胆囊癌微创根治术:单中心逾200例经验
该单中心回顾性研究分析2011年3月至2023年6月接受微创根治性胆囊切除术(MIRC)的胆囊癌患者,最终205例恶性患者纳入肿瘤学结局分析。中位总生存60个月,3年与5年生存率分别为62.3%和42.9%,早期及淋巴结阴性患者生存显著更优,无穿刺孔复发。
要点
- MIRC用于胆囊癌的中位总生存为60个月,5年生存率42.9%
- 早期(T1/T2)患者中位生存66个月,优于局部进展期36个月
- 淋巴结阴性患者中位生存68个月,优于淋巴结阳性34个月
核心结论
- 该单中心迄今最大样本系列记录显示,微创根治性胆囊切除术对胆囊癌具有肿瘤学疗效。
研究设计与样本
- 单中心回顾性分析,采用前瞻性收集的数据,纳入2011年3月至2023年6月接受MIRC的原发性和意外发现胆囊癌患者,最终病理良性者被排除。
主要发现
- 共222例疑似胆囊癌患者接受MIRC,平均年龄49.5±12.5岁,女男比4.2:1。
- 平均手术时间232±55.3分钟,平均出血量153.8±68.4 mL。
- 205例最终病理恶性患者纳入肿瘤学结局分析,总体中位(95%CI)生存60(41-62)个月,3年和5年生存率分别为62.3%和42.9%。
- 早期(T1/T2)胆囊癌中位生存66个月,显著高于局部进展期(T3/T4)的36个月(P<0.0001)。
- 淋巴结阴性患者中位生存68个月,显著优于淋巴结阳性的34个月(P<0.0001);无患者出现穿刺孔复发。
临床怎么用
- 对于经选择的胆囊癌患者,微创根治性胆囊切除术可作为兼具肿瘤学疗效的术式选择,术前分期与淋巴结状态评估对预后判断重要。
局限性
- 为单中心回顾性研究,样本来自单一单位,结论的外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most published studies on minimally invasive radical cholecystectomy (MIRC) for gallbladder cancer (GBC) are limited by a small sample size, disproportionately high incidental GBC patients, and a lack of long-term outcomes. The present study aims to report the long-term oncological outcomes of MIRC in a large series of primary and locally advanced GBC patients. METHODS: A retrospective analysis was conducted using prospectively collected data from primary and incidental GBC patients who underwent MIRC between March 2011 and June 2023. Patients who underwent MIRC and had benign pathology on final histopathological examination were excluded from the analysis. Perioperative short- and long-term oncological outcomes were analyzed. RESULTS: During the study period, 222 patients with suspected GBC underwent MIRC. The mean age was 49.5 ± 12.5 years with a female-to-male ratio of 4.2:1. The mean operative time and blood loss were 232 ± 55.3 min and 153.8 ± 68.4 mL, respectively. 205 patients with malignancy on final histopathology were included in the analysis of oncological outcomes. The overall median (95% CI) survival, 3-year and 5-year survival rates were 60 (41-62) months, 62.3% and 42.9%, respectively. The median survival was significantly higher in early-stage (T1/T2) GBC compared to locally advanced (T3/T4) tumors (66 vs. 36 months, P < 0.0001). Also, node-negative GBC patients had better overall survival than node-positive tumors (68 vs. 34 months, P < 0.0001). None of the patients had port-site recurrence. CONCLUSION: The largest single-unit series published to date documents the oncological efficacy of MIRC for GBC.
引用
- Agarwal AK, Vageesh BG, Javed A, et al. Minimally invasive radical surgery for gallbladder cancer: a single-unit experience of over 200 patients. Surg Endosc. 2025. PMID: 41131380. doi:10.1007/s00464-025-12310-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。